213Bi-DOTATOC is one alpha-labeled analogue of 90Y- and 177Lu-DOTATOC. This somatostatin analogue has previously been labeled with low linear energy transfer (LET) β-emitters, such as 177Lu or 90Y, for tumor therapy. The first synthesis was initiated at the University of New Mexico, Albuquerque NM, USA but as the product is now a generic, several academic centers are exploring this molecule.
The first-in-human experience with 213Bi-DOTATOC targeted alpha therapy (TAT) in patients pretreated with beta emitters was reported in 2014.
Target/Mechanism: Somatostatin receptors
Radiation Type: alpha particle (α)